The board of drug manufacturer Kahira Pharmaceuticals approved unaudited financial results for the fiscal year that ended on June 30, 2014.
These results showed EGP 44.377 million net profit, with a 17.8% decline compared with EGP 53.984 million a year earlier.
The company had posted EGP 50 million net profit before tax for the first nine months of FY13/14, with a rise by 8.9% compared with EGP 46 million in the same period a year earlier.